These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 37011507)

  • 1. Take-Home Naloxone and risk management from the perspective of people who survived an opioid overdose in Stockholm - An analysis informed by drug, set and setting.
    Holmén E; Hammarberg A; Kåberg M; Storbjörk J
    Int J Drug Policy; 2023 May; 115():104021. PubMed ID: 37011507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sweden's first Take-Home Naloxone program: participant characteristics, dose endpoints and predictors for overdose reversals.
    Holmén E; Warnqvist A; Kåberg M
    Subst Abuse Treat Prev Policy; 2023 Apr; 18(1):24. PubMed ID: 37087485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Naloxone and the Inner City Youth Experience (NICYE): a community-based participatory research study examining young people's perceptions of the BC take home naloxone program.
    Mitchell K; Durante SE; Pellatt K; Richardson CG; Mathias S; Buxton JA
    Harm Reduct J; 2017 Jun; 14(1):34. PubMed ID: 28592287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is a randomised controlled trial of take home naloxone distributed in emergency settings likely to be feasible and acceptable? Findings from a UK qualitative study exploring perspectives of people who use opioids and emergency services staff.
    Sampson FC; Hughes J; Long J; Buykx P; Goodacre SW; Snooks H; Edwards A; Evans B; Jones J; Moore C; Johnston S
    BMC Emerg Med; 2024 Apr; 24(1):75. PubMed ID: 38679713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of the distribution of take-home naloxone in low- and middle-income countries and barriers to the implementation of take-home naloxone programs.
    Sajwani HS; Williams AV
    Harm Reduct J; 2022 Oct; 19(1):117. PubMed ID: 36266701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Designing, implementing and evaluating the overdose response with take-home naloxone model of care: An evaluation of client outcomes and perspectives.
    Lintzeris N; Monds LA; Bravo M; Read P; Harrod ME; Gilliver R; Wood W; Nielsen S; Dietze PM; Lenton S; Shanahan M; Jauncey M; Jefferies M; Hazelwood S; Dunlop AJ; Greenaway M; Haber P; Ezard N; Malcom A
    Drug Alcohol Rev; 2020 Jan; 39(1):55-65. PubMed ID: 31774221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overdose and take-home naloxone in emergency settings: A pilot study examining feasibility of delivering brief interventions addressing overdose prevention with 'take-home naloxone' in emergency departments.
    Black E; Monds LA; Chan B; Brett J; Hutton JE; Acheson L; Penm J; Harding S; Strumpman D; Demirkol A; Lintzeris N
    Emerg Med Australas; 2022 Aug; 34(4):509-518. PubMed ID: 35021268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Take-home naloxone programs for suspected opioid overdose in community settings: a scoping umbrella review.
    Moustaqim-Barrette A; Dhillon D; Ng J; Sundvick K; Ali F; Elton-Marshall T; Leece P; Rittenbach K; Ferguson M; Buxton JA
    BMC Public Health; 2021 Mar; 21(1):597. PubMed ID: 33771150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Injection Drug Use Frequency Before and After Take-Home Naloxone Training.
    Colledge-Frisby S; Rathnayake K; Nielsen S; Stoove M; Maher L; Agius PA; Higgs P; Dietze P
    JAMA Netw Open; 2023 Aug; 6(8):e2327319. PubMed ID: 37540514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study protocol for a European, mixed methods, prospective, cohort study of the effectiveness of naloxone administration by community members, in reversing opioid overdose: NalPORS.
    Metrebian N; Carter B; Eide D; McDonald R; Neale J; Parkin S; Dascal T; Mackie C; Day E; Guterstam J; Horsburgh K; Kåberg M; Kelleher M; Smith J; Thiesen H; Strang J
    BMC Public Health; 2023 Aug; 23(1):1608. PubMed ID: 37612698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient characteristics associated with being offered take home naloxone in a busy, urban emergency department: a retrospective chart review.
    O'Brien DC; Dabbs D; Dong K; Veugelers PJ; Hyshka E
    BMC Health Serv Res; 2019 Sep; 19(1):632. PubMed ID: 31488142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Take-Home Naloxone Kits: Attitudes and Likelihood-Of-Use Outcomes from a European Survey of Potential Overdose Witnesses.
    McDonald R; Breidahl S; Abel-Ollo K; Akhtar S; Clausen T; Day E; Kelleher M; McAuley A; Petersen H; Sefranek M; Thiesen H; Strang J
    Eur Addict Res; 2022; 28(3):220-225. PubMed ID: 35114666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid Overdoses and Take-Home Naloxone Interventions: Ethnographic Evidence for Individual-Level Barriers to Treatment of Opioid Use Disorders in Rural Appalachia.
    Garcia V; McCann L; Lauber E; Vaccaro C; Swauger M; Heckert DA
    Subst Use Misuse; 2024; 59(9):1313-1322. PubMed ID: 38635977
    [No Abstract]   [Full Text] [Related]  

  • 14. Factors associated with withdrawal symptoms and anger among people resuscitated from an opioid overdose by take-home naloxone: Exploratory mixed methods analysis.
    Neale J; Kalk NJ; Parkin S; Brown C; Brandt L; Campbell ANC; Castillo F; Jones JD; Strang J; Comer SD
    J Subst Abuse Treat; 2020 Oct; 117():108099. PubMed ID: 32811629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risks and overdose responses: Participant characteristics from the first seven years of a national take-home naloxone program.
    Ericson ØB; Eide D; Lobmaier P; Clausen T
    Drug Alcohol Depend; 2022 Nov; 240():109645. PubMed ID: 36191532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Once I'd done it once it was like writing your name": Lived experience of take-home naloxone administration by people who inject drugs.
    McAuley A; Munro A; Taylor A
    Int J Drug Policy; 2018 Aug; 58():46-54. PubMed ID: 29803097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Who is using take-home naloxone? An examination of supersavers.
    Eide D; Lobmaier P; Clausen T
    Harm Reduct J; 2022 Jun; 19(1):65. PubMed ID: 35717240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Knowledge of Opioid Overdose and Attitudes to Supply of Take-Home Naloxone Among People with Chronic Noncancer Pain Prescribed Opioids.
    Nielsen S; Peacock A; Lintzeris N; Bruno R; Larance B; Degenhardt L
    Pain Med; 2018 Mar; 19(3):533-540. PubMed ID: 28340185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. More than saving lives: Qualitative findings of the UNODC/WHO Stop Overdose Safely (S-O-S) project.
    Walker S; Dietze P; Poznyak V; Campello G; Kashino W; Dzhonbekov D; Kiriazova T; Nikitin D; Terlikbayeva A; Nevendorff L; Busse A; Krupchanka D
    Int J Drug Policy; 2022 Feb; 100():103482. PubMed ID: 35042142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with take-home naloxone kit usage in British Columbia: an analysis of administrative data.
    Lei V; Ferguson M; Geiger R; Williams S; Liu L; Buxton JA
    Subst Abuse Treat Prev Policy; 2022 Mar; 17(1):25. PubMed ID: 35361228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.